Ronan J. Kelly, MD, MBA - Preparing for the Next Leap Forward in Multimodal Management of Esophageal/GEJ Cancer: An Interdisciplinary Tumor Board on Adjuvant Immunotherapy
Manage episode 282420051 series 2857008
Player FM과 저희 커뮤니티의 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education 콘텐츠는 모두 원 저작자에게 속하며 Player FM이 아닌 작가가 저작권을 갖습니다. 오디오는 해당 서버에서 직접 스트리밍 됩니다. 구독 버튼을 눌러 Player FM에서 업데이트 현황을 확인하세요. 혹은 다른 팟캐스트 앱에서 URL을 불러오세요.
Go online to PeerView.com/DCQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Esophageal cancer has a poor prognosis with 5-year survival rates below 35% in the non-metastatic setting. Despite the use of trimodality approaches with chemotherapy, radiation, and surgery, survival benefits remain suboptimal. Promisingly, recent phase 3 evidence suggests that adjuvant immunotherapy can significantly improve disease-free survival in patients with esophageal or gastroesophageal junction (GEJ) cancer. Moreover, a number of other trials are underway studying approaches that harness the patient’s own immune system with immunotherapy in different settings of locally advanced and earlier stage, indicating the expanding role of immunotherapy in the therapeutic management of esophageal or GEJ cancer. Preparing for new treatment strategies that can improve patient outcomes requires the cancer care team of radiation, medical, and surgical oncologists to work in a concerted multidisciplinary approach. This activity will provide a comprehensive and practically-oriented, multidisciplinary overview on the expanding role of immunotherapy in esophageal and GEJ cancer. Radiation and medical oncology experts will offer their insights to optimize the integration and use of immunotherapies in the multimodal management of esophageal and GEJ cancer. Upon completion of this activity, participants should be better able to: Describe the mechanisms by which immunotherapies harness the immune system in the treatment of esophageal and gastroesophageal junction (GEJ) cancers and the rationale for using immune checkpoint inhibition as adjuvant therapy in locally advanced and earlier-stage disease, Evaluate the latest clinical trials and data related to the use of adjuvant immunotherapy in locally advanced and earlier stages of esophageal or GEJ cancer, Develop optimal multidisciplinary treatment plans for patients with locally advanced and earlier-stage esophageal or GEJ cancer, including clinical trial enrollment, based on the available evidence, patient- and disease-related factors, and expert recommendations.